A Phase 1 Dose Escalating Trial of Bortezomib in Combination With Lenalidomide in Patients With Myelodysplasia
Status:
Completed
Trial end date:
2012-03-01
Target enrollment:
Participant gender:
Summary
This study proposes using bortezomib in cohorts of 3-6 patients at the doses of 0.7, 1, and
1.3 mg/m2 on days 1, 4, 8, and 11 to determine the MTD in combination with lenalidomide 10 mg
a day, for 21 days of a 28 day treatment cycle for patients with myelodysplastic syndrome.